Form 4: Avidity Biosciences CEO Exercises and Sells Shares Under 10b5-1 Plan

Avidity Biosciences CEO Sarah Boyce executed stock options and sold shares on March 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 1, 2024, Sarah Boyce, the President and CEO of Avidity Biosciences, exercised stock options to acquire 84,000 shares of common stock at a price of $1.24 per share.
• Simultaneously, Boyce sold 84,000 shares of common stock at a weighted-average price of $20.1346 per share, with individual sales ranging from $20.12 to $20.23.
• These transactions were executed under a pre-arranged 10b5-1 trading plan.
• Following these transactions, Boyce directly owns 112,117 shares of Avidity Biosciences common stock, which includes 106,508 restricted stock units and 4,709 shares acquired through the employee stock purchase plan.
• Boyce also holds options to purchase 1,013,015 shares of common stock, which are fully vested and exercisable.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are part of a pre-planned trading strategy. The CEO is realizing gains, but still holds a significant stake in the company.

Positives

• The exercise of stock options demonstrates the CEO's confidence in the company.
• The sale of shares at a significantly higher price than the exercise price resulted in a substantial profit for the CEO.

Negatives

• The sale of a large block of shares by the CEO could be perceived negatively by some investors, potentially creating short-term selling pressure.

Risks

• The market's reaction to the CEO's stock sale could be unpredictable.
• Further stock sales by the CEO could negatively impact the stock price.

Future Outlook

The document does not contain specific forward-looking statements, but the CEO's continued ownership of a significant number of shares and stock options suggests a long-term commitment to the company.

Industry Context

Insider transactions are common in publicly traded companies, and the use of 10b5-1 plans allows insiders to sell shares in a pre-planned manner to avoid accusations of trading on non-public information. The market will likely assess the CEO's transactions in the context of Avidity Biosciences' overall performance and future prospects.

Comparison to Industry Standards

• Comparing Sarah Boyce's compensation and stock ownership to CEOs of similar-sized biotechnology companies like Alnylam Pharmaceuticals or Ionis Pharmaceuticals would provide context.
• Analyzing the frequency and size of insider transactions at these comparable companies could reveal whether Boyce's recent activity is typical or unusual.
• Reviewing the 10b5-1 trading plans of executives at these companies could also offer insights into industry best practices.

Stakeholder Impact

• Shareholders may react to the CEO's stock sale, potentially impacting the stock price.
• Employees may view the CEO's actions as a reflection of the company's prospects.

Key Dates